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SARS-CoV-2 is associated with new-onset neurological and psychiatric conditions. Detailed clinical data, including factors associated
with recovery, are lacking, hampering prediction modelling and targeted therapeutic interventions. In a UK-wide cross-sectional surveil-
lance study of adult hospitalized patients during the first COVID-19 wave, with multi-professional input from general and sub-specialty
neurologists, psychiatrists, stroke physicians, and intensivists, we captured detailed data on demographics, risk factors, pre-COVID-19
Rockwood frailty score, comorbidities, neurological presentation and outcome. A priori clinical case definitions were used, with cross-
specialty independent adjudication for discrepant cases. Multivariable logistic regression was performed using demographic and clinical
variables, to determine the factors associated with outcome. A total of 267 cases were included. Cerebrovascular events were most fre-
quently reported (131, 49%), followed by other central disorders (95, 36%) including delirium (28, 11%), central inflammatory (25,
9%), psychiatric (25, 9%), and other encephalopathies (17, 7%), including a severe encephalopathy (n¼ 13) not meeting delirium crite-
ria; and peripheral nerve disorders (41, 15%). Those with the severe encephalopathy, in comparison to delirium, were younger, had
higher rates of admission to intensive care and a longer duration of ventilation. Compared to normative data during the equivalent
time period prior to the pandemic, cases of stroke in association with COVID-19 were younger and had a greater number of conven-
tional, modifiable cerebrovascular risk factors. Twenty-seven per cent of strokes occurred in patients <60 years. Relative to those
>60 years old, the younger stroke patients presented with delayed onset from respiratory symptoms, higher rates of multi-vessel occlu-
sion (31%) and systemic thrombotic events. Clinical outcomes varied between disease groups, with cerebrovascular disease conferring
the worst prognosis, but this effect was less marked than the pre-morbid factors of older age and a higher pre-COVID-19 frailty score,
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and a high admission white cell count, which were independently associated with a poor outcome. In summary, this study describes the
spectrum of neurological and psychiatric conditions associated with COVID-19. In addition, we identify a severe COVID-19 encephal-
opathy atypical for delirium, and a phenotype of COVID-19 associated stroke in younger adults with a tendency for multiple infarcts
and systemic thromboses. These clinical data will be useful to inform mechanistic studies and stratification of patients in clinical trials.
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Introduction
COVID-19 causes a multi-system disorder associated with
a broad spectrum of neurological and neuropsychiatric
complications.1,2 Mild disease has been associated with
neurological symptoms, such as headache, anosmia and
ageusia1,3 without major neurological complications.4
Approximately 10–25% of patients hospitalized with
COVID-19 present with or develop a significant neuro-
logical disorder,4–8 the risk of which may increase with
disease severity.1,9 Complications may reflect para- or
post-infectious central and peripheral immune-mediated
syndromes, or rarely direct CNS infection.10,11 We are at
the early stages of understanding the impact of these
neurological complications of COVID-19.
As neurological complications are varied and occur
throughout the disease course, multiple mechanisms have
been proposed. These may include direct viral infection
of endothelium via angiotensin converting enzyme-2
receptors, systemic inflammation resulting in coagulop-
athy, cytokine toxicity, blood–brain barrier disruption,
antibody and cell-mediated autoimmunity and consequen-
ces of prolonged severe illness.2,12–15 These suggested
pathological processes may co-exist, act synergistically
and occur simultaneously in different parts of the nervous
system, causing overlapping clinical presentations.
Studies reporting neurological complications of COVID-
19 have successfully met the pressing need to disseminate
data rapidly to inform pandemic management and re-
search efforts. However, this speed has limited geograph-
ical reach, so there is a paucity of nationwide studies
and limited detailed clinical diagnostic and prognostic
information. This is further hampered by a lack of
unified diagnostic criteria and under-appreciation of over-
lapping presentations. Consequently, the factors predict-
ing recovery remain poorly understood.
To address these gaps, we conducted a UK-wide
surveillance study of neurological and psychiatric compli-
cations of COVID-19 (March–October 2020). National
and cross-specialty recruitment was conducted to identify
common and rarer presentations, and incorporated rigor-
ous clinical case definitions to evaluate overlapping
neurological presentations and determine the factors asso-
ciated with recovery. In this paper, we first deliver an
overview of the main neurological and psychiatric mani-
festations encountered. Then we present more detail on
each category of disorder and perform analyses to try to




Physicians were invited to complete standardized electron-
ic Case Record Forms (CRFs) by the five major profes-
sional neuroscience associations in the UK (Association of
British Neurologists, British Association of Stroke
Physicians, Royal College of Psychiatrists, the Neuro
Anaesthesia and Critical Care Society, and the Intensive
Care Society). This study was approved by the University
of Liverpool (UoL #7725/2020) and the University of
Southampton (ERGO #56504). The British Peripheral
Graphical Abstract
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Nerve Society’s surveillance study for Guillain–Barré
syndrome was performed independently,16 but the case
definitions and data fields were aligned to enable inclu-
sion. Four cases were published as single case studies
(Supplementary Table 1). The UK Health Research
Authority advised that the study did not require review
by a NHS Research Ethics Committee as this was a sur-
veillance study with non-identifiable information.
The CRF included demographics, evidence of SARS-
CoV-2 infection, neurological and non-neurological clinic-
al features, pre-morbid Rockwood frailty score,17 comor-
bidities and medications on admission, risk factors for
stroke, respiratory disease course, requirement for inten-
sive care, laboratory/imaging results and modified Rankin
score (mRS).18 The mRS was captured at two time
points: at nadir and at discharge from hospital or the
first follow-up assessment visit. The mRS was selected for
several reasons. In view of the expected heterogeneity of
neurological conditions, no single scale would have been
considered optimal, and the consensus view was that the
anticipated high proportion of strokes, familiarity of most
clinicians with the mRS and the ease of its administration
made the mRS the best candidate. The CRF was hosted
on ALEA through the Clinical Information Research Unit
at the University of Southampton. Data lock was 14
October 2020.
Inclusion criteria
Physicians were invited to complete a CRF for any adult
patient (18 years) hospitalized with a neurological or
psychiatric presentation and COVID-19, or else develop-
ing these conditions whilst in hospital with COVID-19.
Using World Health Organization criteria, cases were
defined as ‘confirmed COVID-19’ if polymerase chain re-
action (PCR) of respiratory samples or CSF was positive,
or serology was positive for anti-SARS-CoV-2 antibodies.
Cases were defined as ‘probable COVID-19’ if a chest
radiograph or CT was consistent with COVID-19 but
PCR and serology were negative or not done. Finally,
cases were defined as ‘possible COVID-19’ if suspected
on clinical grounds by the notifying clinician but PCR,
serology and chest imaging were negative or not done,2
or if these data were unavailable. Cases of nosocomial in-
fection following admission with a primary neurological
presentation were excluded.
Clinical case definitions
Patients were classified using standardized clinical case
definitions .2,19 Cerebrovascular events were defined as
symptoms, signs and/or neuroimaging consistent with
transient ischaemic attack, ischaemic or haemorrhagic
stroke, or intracranial venous thrombosis. Central inflam-
matory conditions were defined as those involving the
CNS, with evidence of meningeal, parenchymal or vascu-
lar inflammation (CSF white cell count > 4/mm3, and/or
protein > 0.45 g/dl, and/or neuroimaging consistent in-
flammation and/or demyelination).2 For psychiatric disor-
ders, CRFs were assessed by a sub-specialty team of
senior psychiatrists (co-authors TN and TP). Delirium
was defined in accordance with the DSM-5 and the Ten
Societies position statement20: (i) new-onset disturbance
in attention, awareness and cognition, developing over
hours or days, with some fluctuation, not in the context
of a severely reduced level of arousal, such as coma, and
not secondary to medication or substance misuse; and (ii)
encephalopathy attributable to fever/sepsis, and/or hyp-
oxia–ischaemia. Therefore, severe encephalopathy was
defined as those with a severely reduced level of arousal
(a Glasgow coma score 13/15 and/or seizures).
Psychiatric presentations were considered a primary diag-
nosis if there was no evidence of an explanatory neuro-
logical disorder (e.g. psychosis without encephalitis/
delirium). When multiple psychiatric diagnoses were
reported, the primary diagnosis was ascertained in ac-
cordance with Bedford’s hierarchical model,21 which pla-
ces psychiatric conditions in the following order of
primacy: organic disorders (including neurocognitive dis-
order), followed by psychotic disorders, followed by
mood disorders, followed by anxiety disorders, and final-
ly personality/behavioural disorders. Peripheral neuropa-
thies were cases involving the peripheral nervous system
and categorized as inflammatory and non-inflammatory,
on the basis of the reported diagnosis and whether in-
flammation is the sole recognized pathophysiological
cause of this diagnosis; for example, Guillain–Barré syn-
drome is an archetypal inflammatory neuropathy, when
compared to critical illness neuromyopathy.
When cases met multiple clinical case definitions, the
primary definition was determined by blinded adjudica-
tion of the CRF data by three groups of senior authors
representing neurology, psychiatry and stroke. Discrete
clinical case definitions reported in the same patient were
considered ‘overlapping syndromes’, for example,
Guillain–Barré syndrome and an ischaemic cerebrovascu-
lar event. When complications were consistent with the
primary clinical case definition, such as haemorrhage in
acute haemorrhagic leukoencephalopathy, the primary
diagnosis sufficed.
Patients with stroke were compared with those from
the national stroke audit [Sentinel Stroke National Audit
Programme (SSNAP)] over a comparable period in the
preceding year (April—June 2019). Patients presenting
with cerebrovascular events below the age of 60 were
compared with those presenting above the age of 60.
Statistical analysis
Statistical analysis was performed using SAS software
(version 9.4; SAS Institute, Cary, NC, USA), SPSS v26
(IBM) and GraphPad Prism v8.4.3 (GraphPad Software,
LLC). Normality of distribution was assessed using
Kolmogorov–Smirnov tests. Data were analysed using
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descriptive statistics, group comparison tests, chi-squared
tests, z-tests for independent proportions, and univariable
logistic regression. A good outcome was defined as mRS
2 (reflecting no symptoms, slight disability, but independ-
ent) and a poor outcome as mRS >2 (moderate disability
requiring assistance, or worse, including death).
Multivariable logistic regression models were developed
using baseline pre-COVID-19 variables with >80% data
availability. Two sensitivity analyses were carried out for
each model, one adjusting for diagnostic categories, and
one using multiple imputation to account for the potential
effect of missing data. The imputation model used a fully
conditional specification and included the auxiliary varia-
bles weight and mRS at nadir. All hypothesis testing was
two-tailed with alpha <0.05.
Data availability
Study data are available from the authors subject to insti-




Of 314 electronic CRF invitations accepted, 277 (89%)
were submitted. The British Peripheral Nerve Society plat-
form independently contributed an additional 24 cases.
Cases not meeting the inclusion criteria or with incomplete
core data were excluded (Supplementary Fig. 1). Included
cases were from a broad range of sub-specialities and geo-
graphical distribution (Supplementary Figs 2 and 3).
Of 267 included cases, 95 (36%) were female, and 44
(18%) were from Black, Asian and minority ethnic
groups (Table 1). 113 (42%) were below the age of
60 years. COVID-19 was confirmed or probable in 239
(90%) patients, with 28 (10%) defined as possible
COVID-19 disease. The median (IQR) Rockwood frailty
score before COVID-19 was 3 (2–5) (medical problems
well controlled, but not regularly active beyond routine
walking). Median (IQR) of Glasgow coma score on ad-
mission was 15 (14–15). Comorbidities were common,
with 196 (81%) cases having at least one (Table 1). In
addition, 66 (28%) had comorbid neurological disease,
and 22 (10%) had a history of psychiatric illness. The
most common non-neurological symptoms were fever
(172, 73%), cough (139, 67%) and lethargy (124, 68%).
Anosmia and/or ageusia was reported in 21 (18%) cases
(Supplementary Table 2).
Overview of neurological and
psychiatric conditions
Most cases primarily involved the CNS (226, 85%) (Fig.
1). The largest group were cerebrovascular events,
comprising 131 (49%) patients (Figs 1 and 2). The se-
cond most common CNS groups were delirium (28,
11%) and central inflammatory conditions (25, 9%); the
latter comprising mostly demyelination and leukoence-
phalopathy, but also vasculitis, encephalitis, and opsoclo-
nus–myoclonus syndrome (Figs 1 and 2). Psychiatric
presentations (25, 9%) were most commonly new diagno-
ses (19, 76%) but included six patients with an exacerba-
tion of an underlying condition (24%). Those remaining
were all other encephalopathies (17, 7%), including 13
with severe encephalopathy and four with posterior re-
versible encephalopathy syndrome. The peripheral ner-
vous system was primarily involved in 41 (15%) cases,
of which 35 (85%) were inflammatory and six (15%),
were non-inflammatory.
Multiple overlapping diagnoses
A proportion of patients (34, 13%) met multiple primary
clinical case definitions, with each diagnostic group over-
lapping at least two others, and 11 cases (32%) involving
both the CNS and peripheral nervous system (Fig. 3A
and B). The greatest overlap was in the cerebrovascular
(19 cases, 14%), delirium (15, 40%) and central inflam-
matory (11, 4%) groups. Patients with overlapping pre-
sentations more frequently required intensive care (20,
65% versus 56, 26%, P< 0.001) and ventilation (71%
versus 28%, P< 0.001) compared to those meeting a sin-
gle clinical case definition.
Cerebrovascular disorders
Most primary cerebrovascular events were ischaemic
(105, 80%), including large vessel occlusions, small vessel
infarcts and multi-territory infarcts affecting both large
and small vessel distributions. Most cases of intracerebral
haemorrhage were isolated (17, 81%), but four (19%)
were multifocal, and there was considerable overlap with
other clinical case definitions, especially multi-vessel
strokes (Fig. 3C and D). Patients with cerebrovascular
events had a higher frequency of non-CNS thrombotic
complications (e.g. pulmonary embolism, cardiac throm-
bus, renal artery thrombosis) than the rest of the cohort
(11% versus 5%). As compared to historical non-
COVID-19 stroke patients, those in association with
COVID-19 were younger, had a greater number of
comorbidities, and cerebrovascular risk factors (especially,
diabetes mellitus, congestive heart failure, and atrial fib-
rillation), and had a worse outcome (Fig. 4).
Within our cohort, cerebrovascular events occurred in
35 (27%) patients aged <60 years and, relative to those
aged >60 years old (96, 73%), they presented later, with
a median (IQR) onset after respiratory symptoms of
10 days (0–18) compared to 0 days (7 to 7) (P< 0.001).
The younger group also had lower rates of co-morbidities
increasing stroke risk (16, 67% versus 77, 88%), a
higher proportion of multi-vessel occlusion (9, 31%
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versus 11, 15%) and more non-neurological thrombotic
events (6, 18% versus 8, 8%) (Supplementary Table 3).
Central nervous system
inflammatory conditions
The most common complication in the central inflamma-
tory group was leukoencephalopathy, affecting 13 (52%)
cases. Encephalitis was reported in three; in one PCR of
CSF was positive for SARS-CoV-2. Nine cases (43%)
needed ventilation and had acute kidney injury, of which
seven (78%) required renal replacement therapy.
Delirium
Delirium had a bimodal age distribution, the first peak at
30–39 years (4, 14%) (Supplementary Table 4). Relative
to the rest of the cohort delirium was not significantly
Table 1 Patient demographics and clinical characteristics
All patients
Demographics








Sex, n (%) Male 172 (64)
Female 95 (36)





COVID diagnosis, n (%) Confirmed or probable 239 (90)
Possible 28 (10)
Clinical characteristics
ICU admission, n (%) Yes 76 (28)
No 171 (64)
Unknown 20 (8)




Pre-COVID-19 frailty score, median (IQR) 3 (2–5)
At least one co-morbidity, n (%) 196 (81)
Type of co-morbidity, n (%) Any neurological 66 (28)
Any psychiatric 22 (10)
Hypertension 125 (48)
Diabetes mellitus 63 (24)
Atrial fibrillation 43 (18)
Congestive heart failure 19 (10)
Previous TIA/stroke 25 (13)
Number of co-morbidities, median (IQR) 2 (1–4)
Admission GCS, median (IQR) 15 (14–15)
Fever, n (%) 172 (73)
Admission WCC, median (IQR) 8 (6–12)
Admission CRP, median (IQR) 41 (9–140)
Any non-neurological, non-respiratory systemic complication, n (%) 101 (42)
mRS at nadir, median (IQR) 4 (3–5)
mRS at outcome, median (IQR) 3 (2–5)
Improvement in mRS score, n (%) 125 (53)
Admission length in days, median (IQR) 23 (7–48)
Death, n (%) 57 (24)
mRS refers to modified Rankin Scale. Pre-COVID-19 frailty score refers to Rockwood frailty score. For definition of medically significant co-morbidities, see Supplementary
methods. Improvement in mRS score was defined as mRS at outcome < mRS at nadir, or mRS score of 0 at both nadir and outcome.
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associated with established risk factors, such as age,
markers of systemic inflammation and intensive care
(Supplementary Table 5). There were six cases that met
both delirium and psychiatric diagnostic criteria, of which
three were <60 years old. One presented with new onset
paranoid beliefs 48 h prior to delirium; one had profound
anxiety progressing to Capgras syndrome (a delusion of
misidentification); and one developed prominent hallucin-
ation requiring multiple antipsychotic medications with
ongoing symptoms several months after systemic
recovery.
Severe encephalopathy
There were 13 additional cases of severe encephalopathy,
that did not meet a clinical case definition of delirium as
they had a severely reduced level of arousal.20 These se-
vere encephalopathies were characterized by significant
complications, frequently affecting consciousness, namely:
provoked seizures and status epilepticus in younger
patients with no premorbid conditions, cardiac and renal
complications including cardiac arrest in working-age
adults, and seizures in older adults with significant
pre-existing neurological comorbidities (Supplementary
Table 6). Those with this severe encephalopathy (n¼ 13),
in comparison to delirium (n¼ 28), were younger (me-
dian decade 50–59 versus 60–69 years), had higher rates
of admission to intensive care (8, 62% versus 8, 29%)
and ventilation (8, 67% versus 9, 33%) and a longer
median (IQR) duration of ventilation of 11 (0–36) versus
0 (0–13) days.
Psychiatric diagnoses
New psychiatric diagnoses included nine cases of psych-
osis, four cases of depression, two cases of anxiety and a
single case each of catatonia, mania, neurocognitive/de-
mentia-like syndrome and functional neurological
disorder.
Peripheral neuropathies
The peripheral neuropathies reported were predominantly
Guillain–Barré syndrome. Non-inflammatory peripheral
neuropathy cases were mostly critical illness neuromyopa-
thies, albeit without neurophysiological confirmation.
There were no deaths in any patients with peripheral
neuropathy.
Timing of neurological symptoms
In 66 (47%) patients, the onset of neurological disturb-
ance occurred after their respiratory condition improved,
and in 69 (29%), the neurological symptoms predated
the onset of COVID-19 symptoms. Neurological
symptoms started after a median (IQR) of 12 (2–22)
days following onset of respiratory symptoms and lasted
for a median (IQR) of 20 days (6–44) (Fig. 5).
Figure 1 Classification of main neurological diagnoses.
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Figure 2 Magnetic resonance imaging demonstrating the range of neurological complications seen in this study. (A) Territorial
infarct, secondary to internal carotid artery (ICA) dissection in a middle-aged previously fit male: Axial fluid-attenuated inversion recovery image
(i) showing a right middle cerebral artery (MCA) territory infarct following decompressive craniectomy for malignant MCA syndrome despite
treatment with thrombolysis. Reformatted images from a CTangiogram (ii) showing irregularity of the extracranial segment of both internal
carotid arteries, consistent with dissection (arrows), with tight stenosis of the true lumen on the right (arrowhead). (B) Multiple territorial
infarcts in a female >60 years old with hypertension and dyslipidaemia: Diffusion-weighted images (DWI) demonstrate recent infarcts in the right
medial occipital lobe and lentiform nucleus, involving the territories of the right posterior cerebral artery and lenticulo-striate perforators of the
right MCA respectively. (C) Acute lacunar infarcts due to small vessel vasculopathy in a male > 60 years old, with a background of hypertension
and type 2 diabetes: B1000 images (i, ii) and corresponding apparent diffusion coefficient (ADC) maps (iii, iv) from DWI showing multiple tiny
foci of restricted diffusion. (D) Vasculitis in a male >60 years old, with a background of type 2 diabetes, hypertension and hypercholesterolaemia:
T1-weighted SPACE vessel wall imaging of both distal ICAs and proximal MCAs, with curved multiplanar coronal reconstructions along the
course of both proximal MCAs (first column) and perpendicular to the right MCA (second column, at the position of the dotted line).
Pre-treatment pre-contrast (i, ii) and post-contrast images (iii, iv) demonstrate abnormal concentric, long segment vessel wall enhancement
(arrows) of both proximal MCAs. Post-contrast images after treatment with prednisolone and tocilizumab (v, vi) demonstrate treatment
response with resolution of the previous abnormal mural MCA enhancement (arrows). (E) Acute encephalomyelitis with haemorrhage in a
middle-aged male, with a history of chronic obstructive pulmonary disease, who required intensive care and haemofiltration: Coronal FLAIR (i)
and axial gradient echo (ii) images showing focal heterogeneous signal abnormality and swelling of the splenium of the corpus callosum, with
peripheral low signal indicative of haemosiderin staining (arrows). Confluent high signal is present in periventricular and deep white matter of the
parieto-occipital region. (F) Typical imaging appearances of posterior reversible encephalopathy syndrome in a normotensive middle-aged female:
Axial T2 image (i) demonstrating hyperintense signal in subcortical white matter of both occipital lobes, with B1000 image (ii) and ADC map (iii)
from DWI showing no corresponding restricted diffusion.
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Cerebrovascular events were associated with the earliest
onset, with median (IQR) time from respiratory symp-
tom onset to cerebrovascular event of 7.5 (2–16) days.
Interestingly, longer time to onset was observed in the
central inflammatory, psychiatric and peripheral neur-
opathy diagnostic categories.
Clinical outcome and risk factors
Outcome mRS was assessed at a median (IQR) follow-up
time of 30 days (7–60). This was at hospital discharge
(48%), as an inpatient (22%) or an outpatient (29%).
Patients in this study were substantially disabled, since
131 (56%) had an outcome mRS of 2–5; moreover, 57
(24%) patients died. Outcome was assessed in three
ways: whether mRS improved (mRS at outcome versus
mRS nadir), mRS at outcome and death.
Improvement in outcome mRS relative to the mRS
score at nadir of illness was seen in all primary diagnos-
tic categories other than cerebrovascular events (Fig. 6).
There was a significant difference in mRS improvement
across diagnostic groups (Supplementary Table 7,
P< 0.001). Cerebrovascular events improved the least
(39%, P< 0.001), while central inflammatory conditions
improved most (77%, P< 0.03).
Multivariable analysis using baseline variables easily
available at admission, demonstrated a higher probability
of a poor outcome (mRS 2) with older age, a higher
Rockwood frailty score and higher white cell count on
admission. In comparison, the association of outcome
with individual neurological diagnostic categories was
negligible. A similar pattern was observed with mortality
(Table 2).
Discussion
Through a nationwide surveillance study of adults hospi-
talized with COVID-19, conducted through a cross-spe-
cialty collaboration spanning six national physician
associations, we present the broad spectrum of potential
neurological and psychiatric complications of COVID-19,
across central and peripheral nervous systems. Our results
build on existing knowledge,1,4–8,10–12,22 by applying
standardized, internationally agreed, a priori clinical case
definitions and independent, blinded case adjudication to
determe specific diagnostic group membership, and by
Figure 3 Venn diagrams showing overlap of diagnostic groups. The numbers shown here are when all diagnoses were considered, in
addition to the primary neurological diagnosis. The total numbers for several groups are larger in this Figure than the primary diagnosis
flowchart (Fig. 1) due to coexisting diagnoses. (A) Central and peripheral nervous system disease. (B) Primary diagnostic categories (*two cases
of Guillain–Barré syndrome with delirium were not possible to accommodate on this diagram). (C) Stroke group subtypes. (D) Specific stroke
group subtypes. CVST, cerebral venous sinus thrombosis; TIA, transient ischaemic attack.
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presenting detail on the overlap between clinical presenta-
tions. We provide further evidence of a coagulopathy pre-
cipitating stroke in young patients, occurring in the para-
infectious phase of illness, and suggest this group is dis-
tinct to older patients with multiple conventional risk fac-
tors. Nevertheless, despite a younger cohort of patients
with COVID-19 associated stroke compared to non-
COVID-19 stroke patients, conventional, often modifi-
able, risk factors were more frequent even in younger
patients.
Timing of onset
Onset of neurological disease, in days relative to respira-
tory symptoms, varied across different diagnostic catego-
ries. In 29% of cases, neurological symptoms preceded
respiratory symptoms, suggesting occurrence during the
virological, or para-infectious phase, the early part of
which is usually asymptomatic.23 This supports early
mechanisms, such as activation of the innate immune sys-
tem and direct viral effects on endothelial cells. Within
the context of a pandemic, neurological syndromes
described in this study could be a sentinel sign of
COVID-19, and we encourage SARS-CoV-2 testing of
patients with neurological presentations, including acute
encephalopathy, in settings where asymptomatic testing is
not routine. The later presentation of central inflamma-
tory and peripheral nerve presentations, after respiratory
recovery, and the high rates of improvement seen in these




Our comparison with pre-COVID-19 SSNAP data
identified higher rates of young stroke in our COVID-19
cohort, despite reports of a reduction in overall stroke
admissions during the pandemic.24 The underlying mech-
anisms leading to stroke may differ between younger and
older cases, as younger strokes had a significantly delayed
presentation, were associated with fewer comorbidities,
and demonstrated higher rates of both multi-vessel occlu-
sion and of thrombotic complications outside of the
CNS. These findings are supportive of a para-infectious
thrombo-inflammation, potentially driven by endothelitis
and subsequent cytokine release, and in line with
previous reports of elevated serum markers of coagulop-
athy in stroke patients.25 Early administration of
Figure 4 COVID-19 strokes versus historical controls. Comparison between strokes associated with COVID-19 in this study and strokes
from a national UK audit in 2019. (A, B) total number of co-morbidities which are risk factors for stroke (atrial fibrillation, hypertension,
diabetes mellitus, congestive heart failure and previous TIA or stroke). (C) Age distributions. (D) mRS (modified Rankin scale) scores on
discharge from hospital (or death).
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anti-inflammatory therapy has potential benefit, and our
data strengthen the case for trials to consider stroke out-
comes so that this effect can be evaluated. In older cases,
where the highest risk is in the initial days of symptoms,
it is likely that COVID-19 is precipitating stroke similarly
to other acute respiratory infections, through interaction
with existing cerebrovascular risk factors.26
Encephalopathy
Encephalopathy is widely reported in COVID-197,27,28
and, in an undifferentiated form, has been demonstrated
to be an independent predictor of death and poorer func-
tional recovery in survivors.9,29 However, there is a lack
of consensus as to the distinct underlying pathophysi-
ology.30 The presentation of delirium in younger patients,
seen frequently in our cohort, is unusual for a respiratory
illness in the absence of severe hypoxia, and suggests
COVID-19 confers additional risk compared to other
infections. In addition to delirium, we identified distinct
aetiological groups, including posterior reversible enceph-
alopathy syndrome and a severe encephalopathy outside
the accepted definition of delirium.20 This latter syn-
drome may represent excitotoxic injury, such as is seen
following seizures, metabolic disturbance, or an underly-
ing inflammatory or microvascular process. The greater
need for intensive care in this group may represent both
the cause (exposure to potentially ictogenic medications)
and the consequence of seizures. Indeed, multiple overlap-
ping disease mechanisms may be apparent, even within
an individual patient, and further studies are underway
to evaluate this (COVID-CNS).
Clinical outcome
Age and a higher Rockwood frailty score were much
more indicative of outcome than the neurological or psy-
chiatric disorder. It is interesting that the adjusted hazard
ratio of age for outcome (death or hospitalisation) is
10-fold that of neurological disorders.31 Individual disease
groups were heterogeneous and did not demonstrate sig-
nificantly different outcomes, but this requires further
study in larger cohorts. Ongoing assessment of the pre-
dictive power of premorbid frailty will be important as
we see increasing numbers of young people affected. Poor
outcome also associated with a high admission white cell
count, which might be a useful predictor given that this
is usually normal in the early stages of COVID-19.32
Limitations
This study has several limitations. It concerns a specific
population of COVID-19 positive patients requiring ad-
mission to hospital because of neurological or psychiatric
conditions or else developing these complications whilst
in hospital with COVID-19. Hence it would not have
captured neurological symptoms, such as headache, anos-
mia, dysgeusia and mild cognitive dysfunction, generally
looked after in the community or in outpatient services.
Although this study captured data from a breadth of dif-
ferent specialties, there was still under-representation of
psychiatrists, primary care and internal medicine which
may have skewed the study population to more severe
cases. The mRS was used as a clinical outcome measure
but this scale has not been validated for its measurement
properties across the wide spectrum of conditions studied
here. We did not review primary clinical data held locally
by the referring physician, and could not perform an
independent review of data submission quality. Where
possible the original syndromic classification from the
referring team was presumed to be correct. On rare occa-
sions, there was a reclassification of cases based on
senior author panel review.
Figure 5 Timing of onset of neurology. Violin plot
demonstrating distributions of time intervals in days between onset
of respiratory symptoms and onset of neurological symptoms for
each primary diagnostic category. Patients whose neurological
symptoms preceded COVID-19 symptoms were arbitrarily
assigned a value of minus seven days. The Kruskal–Wallis test was
used to determine any significant difference in time intervals
between groups (P< 0.0001). Dunn’s multiple group comparison
test showed a significant difference between stroke and central
inflammatory primary diagnostic groups (P¼ 0.001), stroke and
psychiatric groups (P¼ 0.037), and stroke and peripheral groups
(P¼ 0.003).
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Participation by physicians occurred during an unprece-
dented healthcare and social emergency, during which
clinical service and research teams were stretched. This
has the potential for reporting bias, in particular under-
reporting of mild disease, and potential over-representa-
tion of unusual presentations. These circumstances are
also likely to have contributed to missing clinical data
fields (Supplementary Table 8). Although not the largest
study to date,6 this study provides both granularity of de-
tail and breadth of sub-specialty input. We included cases
from the very beginning of the pandemic and PCR con-
firmation of COVID-19 was not always present, though
COVID-19-associated neurology was an inclusion
criterion.
The SSNAP database is a high-quality rolling national
audit, which captures routine, consecutive, unselected
stroke cases and has a low risk of bias; there is good
overlap with essential data fields in our study since
SSNAP is so comprehensive. We selected a SSNAP data-
base time period from the year preceding the pandemic,
which was comparable both in season and duration to
our study. However, the comparability of these two
cohorts has to be guarded with caution, due to the po-
tential for selection biases in our cohort. The fact that
our findings were similar to those of the SETICOS
study,33 which used a case–control design, provides some
validation of the approach used here.
Conclusions
In summary, this nationwide, cross-specialty study of
neurological and psychiatric manifestations of COVID-19,
has identified older age and a higher pre-COVID-19
frailty score to be associated with poor outcome, and the
effect of these baseline characteristics overshadowed the
effects of specific neurological diagnoses. Presentations
spanned pre-symptomatic, early and later phases of
COVID-19, implying different pathophysiological proc-
esses may occur, and these may act synergistically in
driving neurological complications. Cerebrovascular
events were the most common complication and, in
young as opposed to older patients, COVID-19-associated
events occurred later after respiratory symptom onset,
supportive of thrombo-inflammation and systemic coagul-
opathy, and this requires further study. A severe enceph-
alopathy beyond the clinical definition of delirium occurs
during COVID-19. Future work must focus on longer
Figure 6 Recovery from neurological condition. Bubble plots displaying the relationship between mRS (modified Rankin scale) at nadir of
illness whilst in hospital and mRS at outcome assessment, within individual diagnostic categories. Bubble area corresponds to patient number.
Line of equivalence is shown in red: cases below the line improved, cases above the line got worse, while cases on the line stayed the same.
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term follow up of specific disease groups, and mechanis-
tic studies using neuroimaging and biosamples to better
characterize pathophysiology.
Supplementary material
Supplementary material is available at Brain
Communications online.
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OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Outcome variable: MRS score at outcome >2
Age (10-year age groups) 1.67 (1.26, 2.22) <0.001 1.66 (1.23, 2.25) 0.001 1.64 (1.28, 2.11) <0.001
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Clinical frailty scale (Rockwood) 1.51 (1.13, 2.02) 0.005 1.48 (1.08, 2.03) 0.014 1.49 (1.16, 1.92) 0.002
Pre-existing neurological disease 1.05 (0.39, 2.87) 0.920 1.38 (0.47, 4.10) 0.560 1.45 (0.58, 3.58) 0.425
Hypertension 0.70 (0.30, 1.65) 0.418 0.75 (0.31, 1.81) 0.517 0.68 (0.32, 1.48) 0.333
Diabetes 1.16 (0.46, 2.98) 0.751 0.96 (0.36, 2.55) 0.928 1.73 (0.74, 4.00) 0.203
Log10 white cell count at admission 7.51 (1.20, 46.92) 0.031 6.56 (1.01, 42.53) 0.049 6.62 (1.31, 33.58) 0.023
Cerebrovascular event diagnosis 2.84 (0.72, 11.22) 0.136
Central inflammatory diagnosis 1.68 (0.39, 7.33) 0.490
Delirium diagnosis 0.94 (0.24, 3.67) 0.932
Psychiatric diagnosis 0.65 (0.13, 3.26) 0.600
Other encephalopathy diagnosis 0.94 (0.16, 5.70) 0.950
Peripheral neuropathy diagnosis 2.45 (0.47,12.87) 0.289
Outcome variable: patient death
Age (10-year age groups) 1.50 (1.12, 2.00) 0.007 1.42 (1.06, 1.91) 0.020 1.48 (1.14, 1.92) 0.003
Sex at birth (Male) 1.13 (0.50, 2.58) 0.762 1.17 (0.50, 2.75) 0.714 1.31 (0.63, 2.70) 0.473
Non-white ethnic group 1.84 (0.53, 6.34) 0.334 1.82 (0.52, 6.40) 0.353 1.39 (0.45, 4.25) 0.566
Clinical frailty scale (Rockwood) 1.65 (1.28, 2.13) <0.001 1.56 (1.20, 2.04) 0.001 1.54 (1.23, 1.93) <0.001
Pre-existing neurological disease 0.62 (0.24, 1.59) 0.318 0.79 (0.30, 2.08) 0.630 0.89 (0.39, 2.06) 0.789
Hypertension 0.56 (0.24, 1.30) 0.179 0.58 (0.25, 1.38) 0.219 0.47 (0.21, 1.03) 0.059
Diabetes 1.06 (0.43, 2.62) 0.905 0.98 (0.39, 2.48) 0.964 1.77 (0.78, 3.97) 0.170
Log10 white cell count at admission 1.76 (0.33, 9.35) 0.507 1.46 (0.24, 8.74) 0.677 2.35 (0.55, 10.02) 0.249
Cerebrovascular event diagnosis 2.09 (0.58, 7.52) 0.262
Delirium diagnosis 0.84 (0.22, 3.26) 0.798
Psychiatric diagnosis 0.48 (0.05, 5.05) 0.544
Other encephalopathy diagnosis 0.74 (0.07, 8.08) 0.803
Multivariable logistic regression analysis of mRS score at outcome >2 and patient death. Patients could have multiple diagnoses. Inflammatory and peripheral neuropathy diagnoses
were excluded from the patient death analysis, as no deaths occurred in these groups.
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